HeartMate 3 in Lowest INTERMACS Profile Cohort: The Swiss Experience
- 1 November 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Asaio Journal
- Vol. 63 (6), 752-758
- https://doi.org/10.1097/mat.0000000000000589
Abstract
New generation devices for long-term mechanical circulatory support are centrifugal pumps having fully magnetically levitated rotors to reduce blood trauma. Recently, the novel HeartMate 3 was cleared for clinical application in Switzerland. In two Swiss University Hospitals part of the “Lausanne–Geneva Transplantation Network,” 10 consecutive patients in end-stage heart failure received the HeartMate 3. Device implantation criteria were persistent low output syndrome despite optimal medical treatment. The primary end-point of the study was survival or transplantation to 90 days on the device. Five patients (50%) were in INTERMACS class 1 and 2 (two were under venoarterial extracorporeal membrane oxygenation [VA-ECMO]), and five were in class 3 and 4. The indication was bridge-to-transplant in seven patients, and destination therapy in three. Two patients (20%) received concomitant aortic valve surgery. Four patients (40%) required temporary right ventricle support (tRVAD) for a mean of 8 ± 1.5 days. Bleeding requiring surgical revision occurred in five (50%) patients, two during the tRVAD support. At the 90 day end-point, survival was 90%, one (10%) died due to respiratory failure. Three (30%) experienced critical illness polyneuropathy. Two had body temperature over 38.5°C for more than 7 days after implant, without infections. Two (20%) had late driveline infection. The pump allowed rapid improvement of patients’ clinical conditions even in severely compromised patients. Postoperative bleeding occurred in the setting of anticoagulation. No hemolysis or pump thrombosis occurred. Fever occurred frequently but was not associated with mortality. Hemodynamic support was consistent over time without significant adverse events.Keywords
This publication has 23 references indexed in Scilit:
- Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomesEuropean Journal of Cardio-Thoracic Surgery, 2016
- Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for HemocompatibilityAsaio Journal, 2016
- Role of long‐term mechanical circulatory support in patients with advanced heart failureInternal Medicine Journal, 2016
- Seventh INTERMACS annual report: 15,000 patients and countingThe Journal of Heart and Lung Transplantation, 2015
- Mechanical Ventricular Assistance as Destination Therapy for End-Stage Heart Failure: Has it Become a First Line Therapy?Frontiers in Surgery, 2015
- Hemocompatibility of Axial Versus Centrifugal Pump Technology in Mechanical Circulatory Support DevicesArtificial Organs, 2015
- Left Ventricular Assist DevicesJournal of the American College of Cardiology, 2015
- Outcomes of Patients Implanted With a Left Ventricular Assist Device at Nontransplant Mechanical Circulatory Support CentersThe American Journal of Cardiology, 2015
- The war against heart failure: the Lancet lectureThe Lancet, 2015
- Clinical outcome and quality of life of patients surviving 20 years or longer after heart transplantationTransplant International, 2014